Insulin-like growth factor-I receptor - a potential therapeutic target in medulloblastomas.

Medulloblastomas represent nearly 25% of all paediatric intracranial neoplasms. These highly malignant tumours arise from the cerebellum and affect predominantly children between the ages of 5 and 15. Although the aetiology of medulloblastomas has not been elucidated, several reports show that the insulin-like growth factor-I (IGF-I) signalling system is highly activated in medulloblastoma cell lines, medulloblastoma animal models and medulloblastoma biopsies, suggesting its contribution to the development and/or progression of these tumours. In addition, reports from multiple laboratories confirm a critical role for the IGF-I receptor (IGF-IR) in the process of cellular transformation. Taken together, these observations prompt the investigation of different strategies to impair the function of IGF-IR as a potential therapeutic tool, which by compromising growth and survival of medulloblastoma cells could supplement conventional therapeutic regiments against these malignant neoplasms of childhood.